Disease Domain | Count |
---|---|
Neoplasms | 3 |
Nervous System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Antibody drug conjugate (ADC) | 1 |
Target |
Mechanism NQO1 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism APE1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MST1R inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date25 Jan 2024 |
Sponsor / Collaborator |
Start Date02 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GNQ-9 ( NQO1 ) | Glioma More | Preclinical |
Zt/g4-maytansinoid(Texas Tech Univeristy) ( MST1R x Tubulin ) | Neoplasms More | Preclinical |
MGAP-9 ( APE1 x MGMT ) | Glioblastoma More | Preclinical |